Comparison of adenocarcinoma (ACA) and squamous cell carcinoma (SCC) of the uterine cervix in a sub-optimally screened cohort: A population-based epidemiologic study of 51,842 women in Brazil

Nogueira-Rodrigues, Angélica; Ferreira, Carlos Gil; Bergmann, Anke; Aguiar, Suzana Sales de; Thuler, Luiz Cláudio Santos

doi:10.1016/j.ygyno.2014.08.014

Cited by 18 publications

(20 citation statements)

References 41 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Population-based studies have shown that most patients with stage IB–IIA CC underwent radical surgery rather than RT. 10 – 12 One randomized study found that the survival outcomes between radical hysterectomy and primary RT were similar for stage IB–IIA cervical squamous cell carcinoma (SCC), whereas radical surgery was a better choice for patients with cervical adenocarcinoma. 13 However, there is still ongoing debate regarding the optimal local treatment modalities for early-stage CC.…”

Section: Introductionmentioning

confidence: 99%

Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer

Zhang

et al. 2017

CMAR

View full text Add to dashboard Cite

IntroductionThere is an ongoing debate regarding the optimal local treatment modalities for stage IB1 and IIA1 cervical cancer. The aim of this study was to determine whether radical hysterectomy or definitive radiochemotherapy is superior in stage IB1 and IIA1 cervical squamous cell carcinoma (SCC).MethodsFrom 1990 to 2010, a total of 3,769 patients with stage IB1 and IIA1 cervical SCC were included from the Surveillance, Epidemiology, and End Results database and were stratified according to whether they received radical hysterectomy or primary radiochemotherapy. Propensity score-matching (PSM) methods were used to balance patient baseline characteristics. Cancer-specific survival (CSS) and overall survival (OS) were compared between the two groups.ResultsOf the 3,769 patients, 3,653 (96.9%) and 116 (3.1%) patients received radical hysterectomy and definitive radiochemotherapy, respectively. Radiochemotherapy was rarely used for definitive treatment prior to 2000. Before PSM, patients who were older, of black ethnicity, and with larger tumor size and stage IIA1 disease were more likely to receive definitive radiochemotherapy. A total of 116 pairs were completely matched using PSM. The local treatment modalities had no effect on CSS or OS in either unmatched or matched populations. In the matched population, the 8-year CSS rates were 82.1% and 76.5% in surgery and radiochemotherapy groups, respectively (p=0.382). The 8-year OS rates were 74.6% and 67.8% in surgery and radiochemotherapy groups, respectively (p=0.205).ConclusionOur population-based study suggests that there is no clear local treatment of choice on survival outcomes between radical hysterectomy and definitive radiochemotherapy in patients with stage IB1 and IIA1 cervical SCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer

Zhang

et al. 2017

CMAR

View full text Add to dashboard Cite

show abstract

“…A decreasing number of cervical cancer cases and an increasing proportion of glandular histological type can thus be considered as indications of effective screening through cytological tests. A recent report from Brazil with more than 50,000 cervical cancer cases registered over the period 2000-2009 showed an increasing proportion of glandular histological type (10% to 16%), but these are still considered modest values 28. The proportion of glandular histological type over the period 2001-2012 was 21%-26% for the Campinas region and 8%-16% for the Curitiba region 29.…”

mentioning

confidence: 98%

Incidence rates and temporal trends of cervical cancer relating to opportunistic screening in two developed metropolitan regions of Brazil: a population-based cohort study

et al. 2019

View full text Add to dashboard Cite

Cervical cancer remains an important burden in relation to women's health, especially in places with limited resources. The Brazilian government estimated that there would be 16,370 new cases in 2018, 1 with great regional variability. Thus, cervical cancer was placed as between the first and fourth most prevalent forms of cancer among women. 1,2 Cervical cancer and its precursor lesions can be detected by screening. The success of population screening programs relates to their level of organization. Organized programs have defined target populations (age, screening interval and satisfactory access), predefined treatment algorithms, management teams, structures for quality assurance, surveillance systems, enough coverage and population education. Such programs have the potential to decrease cervical cancer rates by 80%. 3 In contrast, there are opportunistic screening programs, such as the official population-screening program of the Brazilian National Health System (Sistema Único de Saúde, SUS). There is no registration system to control the screened or unscreened population and cytological tests are performed opportunistically, as a result of recommendations made during routine medical consultations, based on presence of increased risk of developing cancer, or through self-referral. The Brazilian program indicates that conventional cytological tests should be performed every three years, after two consecutive negative tests with a one-year interval between them, for women aged 25 to 64 years. 4 However, the age range and test interval recommendations are

show abstract

“…This histological type was also associated with a lower risk of presentation in advanced stage, according to a study based on secondary data about 51.842 women in Brazil, from 2000 to 2009. 25 This could explain, at least partially, the fact that screening is, in general, less benefitial for women diagnosed with adenocarcinoma. 26 Black and indigenous women, as well as single, divorced and widowed, had greater odds of developing both localized and advanced disease at diagnosis when compared to white women and married women, even after adjustment for the effect of age.…”

Section: Discussionmentioning

confidence: 99%

Tendências temporais e fatores associados ao diagnóstico em estágio avançado de câncer do colo uterino: análise dos dados dos registros hospitalares de câncer no Brasil, 2000-2012*

Renna¹,

Silva²

2018

Epidemiologia e Serviços de Saúde

View full text Add to dashboard Cite

65.843 cases were analyzed; the median interval between diagnosis and treatment was 59 days; the percentage of advanced staging increased, annual percent change 1.10% (95%CI 0.80;1.50); women with higher education (compared to unlettered) had less odds of late stage diagnosis (OR=0.38; 95%CI 0.31;0.47); among indigenous (OR=2.38; 95%CI 1.06;5.33) and black women (OR=1.16; 95%CI 1.02;1.31), compared to white, and in the North region (OR=2.55; 95%CI 2.26;2.89), compared to the Southeast, the odds was higher; other factors positively related to advanced stage were 'age', 'histology', and marital status'. Conclusion Inequities affect the odds of late stage diagnosis of cervical cancer.

show abstract

Comparison of adenocarcinoma (ACA) and squamous cell carcinoma (SCC) of the uterine cervix in a sub-optimally screened cohort: A population-based epidemiologic study of 51,842 women in Brazil

Cited by 18 publications

References 41 publications

Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer

Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer

Incidence rates and temporal trends of cervical cancer relating to opportunistic screening in two developed metropolitan regions of Brazil: a population-based cohort study

Tendências temporais e fatores associados ao diagnóstico em estágio avançado de câncer do colo uterino: análise dos dados dos registros hospitalares de câncer no Brasil, 2000-2012*

Contact Info

Product

Resources

About